ABI
UTHR icon

Adamant Biomedical Investments’s United Therapeutics UTHR Stock Holding History

Adamant Biomedical Investments’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$906K Sell
7,000
-8,000
-53% -$1.03M 0.22% 83
2014
Q3 		$1.93M Buy
+15,000
New +$1.55M 0.48% 58

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Adamant Biomedical Investments's UTHR Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its United Therapeutics (UTHR) stake by 53% in Q4 2014, selling an estimated $1.03M and leaving 7,000 shares worth $906K. The position accounts for 0.22% of the portfolio, ranked #83.

Adamant Biomedical Investments first reported a position in UTHR in Q3 2014 and has held it in 2 quarters since. The position peaked at $1.93M in Q3 2014. 334 funds tracked by Wall St. Rank hold UTHR as of Q4 2014.

  • Adamant Biomedical Investments held 7,000 shares of United Therapeutics worth $906K as of Q4 2014.
  • Adamant Biomedical Investments sold 8,000 United Therapeutics shares in Q4 2014, an estimated $1.03M.
  • United Therapeutics made up 0.22% of Adamant Biomedical Investments's portfolio in Q4 2014, its #83 holding.
  • Adamant Biomedical Investments first reported a position in United Therapeutics in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's United Therapeutics position peaked at $1.93M in Q3 2014.
  • 334 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.